Test Price
400 AED✅ Home Collection Available
Uterus, Adnexa & Fibroid Biopsy Analysis in UAE | Histopathology & Molecular Assessment
Executive Summary & Core Metrics
Clinical Summary: Definitive histopathological and molecular evaluation of uterine, adnexal, and fibroid tissue for accurate diagnosis of benign conditions (e.g., leiomyoma, adenomyosis) and malignant neoplasms (e.g., endometrial carcinoma, ovarian cancer). Integrated immunohistochemical and LC‑MS/MS analysis enhances diagnostic precision for treatment planning and oncological risk stratification.
Price: 400 AED | Turnaround Time: 4 Working Days | Methodology: H&E + IHC + Molecular Pathology (LC‑MS/MS when indicated) | Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. | Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This biopsy analysis provides a comprehensive histopathological and molecular evaluation of uterine, adnexal, and fibroid tissue specimens. The integrated workflow begins with formalin‑fixed paraffin‑embedded (FFPE) processing and haematoxylin and eosin (H&E) staining, followed by targeted immunohistochemistry (IHC) panel profiling for receptor status, proliferation markers, and tumour subtype differentiation. When clinically indicated, liquid chromatography‑tandem mass spectrometry (LC‑MS/MS) is employed for quantitative proteomic and metabolomic profiling to detect early‑stage malignant transformation and genetic susceptibility markers. All procedures are conducted under ISO‑15189 accreditation standards within the DNA Labs UAE facility in Dubai Healthcare City.
| Feature | Our Test (ISO Lab) | Closest UAE Alternative |
|---|---|---|
| Methodology | H&E + IHC + Molecular Pathology (LC‑MS/MS when indicated) | Standard H&E only |
| Turnaround Time | 4 Working Days | 7–10 Working Days |
| Price (AED) | 400 | 450–600 |
| Report Detail | DHA‑compliant digital report with clinical interpretation, IHC panel summary, and integrated molecular risk flags | Basic pathology report without genetic or proteomic insights |
Physician Insight & Safety Protocols
“This comprehensive histopathological and molecular biopsy panel is central to the definitive diagnosis of uterine, adnexal, and fibroid pathology. While the results yield critical diagnostic data, they must be interpreted in conjunction with full clinical history, imaging findings, and gynaecological examination. Patients should not alter or stop any prescribed medication without explicit instruction from their treating physician.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Important Safety Advisory
Do not discontinue any prescribed medication, including anticoagulant therapy, without prior consultation with your physician. Abrupt cessation may increase the risk of thromboembolic events or complicate biopsy procedural safety.
Exclusion Criteria & Emergency Red Flags
- Active pelvic infection or systemic sepsis at the time of biopsy procedure.
- Uncorrected coagulopathy or inability to safely pause anticoagulant therapy after physician clearance.
- Suspected or confirmed ectopic pregnancy; high‑risk pregnancy where invasive tissue sampling is contraindicated.
- Post‑procedural emergency signs: heavy vaginal bleeding, severe pelvic pain, fever exceeding 38°C, or syncope – seek immediate emergency medical care.
Patient FAQ & Clinical Guidance
1. Why is a biopsy preferred over imaging alone for uterine or fibroid evaluation?
Imaging techniques such as ultrasound or MRI provide structural information but cannot reliably differentiate between benign leiomyoma, adenomyosis, and malignant pathology. Histopathological analysis remains the gold standard for definitive tissue diagnosis, treatment planning, and determining the need for adjuvant therapies.
2. How are the tissue samples collected and processed?
Specimens are obtained via image‑guided or surgical biopsy performed exclusively within a hospital setting. The tissue is immediately fixed in 10% neutral‑buffered formalin and transported to our ISO‑accredited laboratory for processing. After fixation, the tissue undergoes paraffin embedding, microtomy, H&E staining, IHC profiling, and, if indicated, LC‑MS/MS molecular analysis. Complete results are available within 4 working days.
3. Are there any genetic markers evaluated in this biopsy panel?
Yes, when clinically warranted, the molecular pathology component includes assessment of tumour suppressor gene expression, microsatellite instability, and hormone receptor status (ER/PR). These markers aid in risk stratification, hereditary cancer syndrome screening, and selection of targeted therapies.
4. What should I do if I experience unexpected symptoms after the biopsy?
Mild cramping or spotting is common and resolves with standard analgesia. However, if you experience heavy vaginal bleeding, severe pelvic pain, fever above 38°C, or feel faint, seek immediate medical attention at the nearest emergency department.
UAE Regulatory & Data Privacy Adherence
Data Protection & Confidentiality: All patient data, biopsy records, and diagnostic reports are processed and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. These regulations ensure that your health information is collected, transmitted, and archived under strict encryption and access‑control protocols.
Clinical Safety & Patient Consent: All biopsy procedures and laboratory analyses adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, which governs informed consent, procedural safety standards, and professional accountability across UAE healthcare facilities.
Accreditation & Oversight: DNA Labs UAE operates under DHA Facility License Number 1143 and maintains ISO 15189 accreditation for medical laboratory quality and competence.
Clinical & Logistical Metadata
| Test Name | Uterus, Adnexa & Fibroid Biopsy Analysis (Histopathology + IHC + Molecular Pathology) |
| Price (AED) | 400 |
| Turnaround Time | 4 Working Days |
| Sample Type / Matrix | Tissue Biopsy (Uterus, Adnexa, Fibroid) – Hospital Extraction Only: sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | H&E Staining, Immunohistochemistry (IHC) Panel, LC‑MS/MS Molecular Profiling (when indicated) |
| ICD-10-CM Code | D25.9, Z12.4 |
| LOINC Code | 44664-0 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians